A novel mechanism of action, inhibiting inflammatory pathways important in the pathogenesis of inflammatory skin diseases
Teres Bio, Inc’s lead asset, TER-101, has a novel mechanism of action and inhibits inflammatory pathways important in the pathogenesis of inflammatory skin disease, including atopic dermatitis. TER-101 has extensive non-clinical testing completed. In a Phase II study completed in patients with moderate to severe atopic dermatitis, topical TER-101 demonstrated improvement in atopic dermatitis signs and symptoms and was generally well tolerated. In December 2020, Teres Bio initiated studies with topical TER-101 for the treatment of mild or moderate atopic dermatitis. Find out more at: clinicaltrials.gov.